Table 3.
Antidepressant use during pregnancy and the risk of major congenital malformations in a cohort of depressed pregnant women
| Exposed during the first trimester of pregnancy n=3640 |
||||||||
|---|---|---|---|---|---|---|---|---|
| Unexposed n=14 847 |
SSRI n=2327 |
SNRI n=738 |
TCA n=382 |
Other antidepressants n=193 |
Crude prevalence OR (95% CI) | Adjusted* prevalence OR (95% CI) | ||
| Major congenital malformations overall | 1650 (11.1) | 279 (12.0) | 91 (12.3) | 51 (13.4) | 21 (10.9) | Non-exposed | Ref. | Ref. |
| SSRI | 1.09 (0.95 to 1.25) | 1.07 (0.93 to 1.22) | ||||||
| SNRI | 1.12 (0.89 to 1.41) | 1.10 (0.87 to 1.38) | ||||||
| TCA | 1.23 (0.91 to 1.67) | 1.16 (0.86 to 1.56) | ||||||
| Other antidepressants | 0.96 (0.61 to 1.52) | 0.93 (0.59 to 1.47) | ||||||
*Adjusted for maternal age, welfare status, diabetes, hypertension, asthma and other medication uses including benzodiazepines as well as healthcare usage in the year prior and during the first trimester.
SNRI, serotonin–norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitors; TCA, tricyclic antidepressants.